Navigation Links
RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage
Date:2/25/2015

ROCKVILLE, Md., Feb. 25, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it has received an Israeli patent with claims for preventing, inhibiting or reducing heart tissue deterioration, injury or damage, and for restoring heart tissue.  The patent includes claims using thymosin beta 4, various fragments and analogues.  The patent will expire in July 2026.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products. RGN-259, the Company's ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx's clinical development efforts in the U.S.  RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK. The Company's partners are in various stages of development of RGN-259 for dry eye syndrome in their respective territories.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  There can be no assurance that any issued patents or licenses held by the Company or patent applications filed by the Company in the U.S. or any other country will result in future value.  Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE RegeneRx Biopharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. RegeneRx Releases Letter to Shareholders
2. AtheroNova Receives Additional Notices of Debt Acceleration
3. Lumicera Receives URAC Specialty Pharmacy Accreditation
4. AtheroNova Receives Notice of Issuance of Its 3rd US Patent
5. Vermillion Receives ISO 13485 Certification for Companys Quality Management System
6. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewings Sarcoma
7. Pressure BioSciences Receives First Purchase Order for its Barozyme HT48 High-throughput System
8. Advanced Prenatal Therapeutics Receives Notice of Allowance for Preeclampsia Device
9. CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
10. AliveCor Receives CE Mark on Atrial Fibrillation Algorithm
11. NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 16, 2019 , ... Steven C. Bilt, Chief Executive Officer ... business performance in the dental industry during a panel discussion at Dykema’s 6th Annual ... at the Omni Dallas Hotel in Dallas, Texas. , Bilt co-founded Smile Brands Inc. ...
(Date:7/17/2019)... ... , ... For the second year in a row, Astro Pak is honored to be named ... County Business Journal, which is the second largest business journal in California. In 2018, Astro ... honor of ranking third place in the medium size employer category. For this year, Astro ...
(Date:7/17/2019)... ... 17, 2019 , ... Careers in emergency medical services (EMS) ... Phoenix, Unitek EMT provides U.S. and international residents with an exceptional alternative for ... dream careers without spending years in school. Over the course of 14 days, ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... July 17, 2019 , ... ... offering fresh, insightful, honest perspectives on today’s issues affecting humanity at practical and ... p.m. PST on Saturday, July 20, 2019. , Guruji Mahendra Trivedi offers ...
(Date:7/17/2019)... PORTLAND, Ore. (PRWEB) , ... July 17, 2019 , ... ... way, at which damage to the teeth could occur, from the accident scene, to ... done before and created a paradigm shift for treatment. , They identified seven points, ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... ... to Eastern Kentucky University’s online Family Nurse Practitioner program. The honor is given ... in distance education. , The Catalyst Awards honor institutions from around the ...
(Date:7/17/2019)... IRVINE, Calif. (PRWEB) , ... July 17, 2019 ... ... of enterprise-wide solutions to health plans participating in Medicare Advantage, Medicaid, and Marketplace ... solution for Providers featuring Electronic Health Records (EHR) integration at ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... administrators of critical access hospitals. , The men and women included on this ... hospital expansions, mergers and EHR implementations as well as the construction of satellite ...
Breaking Medicine News(10 mins):